- Cost of Tuberculosis Treatment: Evidence from Iran’s Health System
-
Vahid Bay, Payam Tabarsi, Aziz Rezapour, Sima Marzban, Ehsan Zarei
-
Osong Public Health Res Perspect. 2017;8(5):351-357. Published online October 31, 2017
-
DOI: https://doi.org/10.24171/j.phrp.2017.8.5.09
-
-
5,455
View
-
43
Download
-
8
Crossref
-
 Abstract
 PDF
- Objectives
This study aimed to estimate the cost of smear-positive drug-susceptible pulmonary tuberculosis (TB) treatment of the patients in the Azadshahr district, Golestan Province, Iran. MethodsIn this retrospective study, all new smear positive pulmonary TB patients who had been registered at the district’s health network between April, 2013 and December, 2015 and had successfully completed their treatment were entered into the study (45 patients). Treatment costs were estimated from the provider’s perspective using an activity-based costing (ABC) method. ResultsThe cost of treating a new smear-positive pulmonary TB patient was US dollar (USD) 1,409.00 (Iranian Rial, 39,438,260), which can be divided into direct and indirect costs (USD 1,226.00 [87%] and USD 183.00 [13%], respectively). The highest cost (58.1%) was related to care and management of TB patients (including 46.1% human resources costs and 12% directly-observed treatment, short course implementation) and then respectively related to hospitalization (12.1%), supportive activity centers (11.4%), transportation (6.5%), medicines (5.3%), and laboratory tests and radiography (3.2%). ConclusionUsing disease-specific cost studies can help the healthcare system management to have correct insight into the financial burden created by the disease. This can subsequently be used in prioritization, planning, operational budgeting, economic evaluation of programs, interventions, and ultimately in disease management.
-
Citations
Citations to this article as recorded by  - Changes in incidence and clinical features of tuberculosis with regard to the COVID-19 outbreak in Southern Iran
Mohammad Javad Fallahi, Mohammad Nazemi, Ali Zeighami, Reza Shahriarirad
BMC Infectious Diseases.2024;[Epub] CrossRef - Costs of services and funding gap of the Bangladesh National Tuberculosis Control Programme 2016–2022: An ingredient based approach
Md. Zahid Hasan, Sayem Ahmed, Zeenat Islam, Farzana Dorin, Md. Golam Rabbani, Gazi Golam Mehdi, Mohammad Wahid Ahmed, Tazeen Tahsina, Shehrin Shaila Mahmood, Ziaul Islam, Kevin Schwartzman
PLOS ONE.2023; 18(6): e0286560. CrossRef - Distribution incidence, mortality of tuberculosis and human development index in Iran: estimates from the global burden of disease study 2019
Hossien Fallahzadeh, Zaher Khazaei, Moslem Lari Najafi, Sajjad Rahimi Pordanjani, Elham Goodarzi
BMC Public Health.2023;[Epub] CrossRef - Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018
Behzad Kiani, Amene Raouf Rahmati, Robert Bergquist, Soheil Hashtarkhani, Neda Firouraghi, Nasser Bagheri, Elham Moghaddas, Alireza Mohammadi
BMC Public Health.2021;[Epub] CrossRef - Healthcare utilization patterns and economic burden of animal bites
Vahid Bay, Aziz Rezapour, Mehdi Jafari, Mohammad Reza Maleki, Irvan Masoudi Asl
Journal of Acute Disease.2021; 10(4): 142. CrossRef - An Analysis of the Survival Probability of Tuberculosis Patients with Right Censored and Interval Censored Observation in Zahedan during 2014 - 2016
Mohammad Hossein Dehghan, Seyyed Mohammad Hashemi Shahri, Mojgan Salari
Zahedan Journal of Research in Medical Sciences.2019;[Epub] CrossRef - Extent and determinants of catastrophic health expenditure for tuberculosis care in Chongqing municipality, China: a cross-sectional study
Weixia Duan, Wen Zhang, Chengguo Wu, Qingya Wang, Ya Yu, Hui Lin, Ying Liu, Daiyu Hu
BMJ Open.2019; 9(4): e026638. CrossRef - Demographic, socio-economic and behavior as risk factors of tuberculosis in Malaysia: a systematic review of the literature
Nur Adibah Mohidem, Zailina Hashim, Malina Osman, Rafiza Shaharudin, Farrah Melissa Muharam, Punitha Makeswaran
Reviews on Environmental Health.2018; 33(4): 407. CrossRef
|
